Background. Although immunodeficiency predisposes to CAPD peritonitis with fungal or unusual organisms, the role of immunosuppression as a predisposing factor for CAPD peritonitis, as well as the outcome of such episodes, remains uncertain. Methods. The incidence, spectrum of infectious organisms, and outcome of CAPD peritonitis was retrospectively reviewed in 39 immunosuppressed and 146 nonimmunosuppressed patients treated with CAPD over the calendar year 1993. Results. Immunosuppressed patients were younger (mean 44 vs 57 years, P< 0.001) and had an increased incidence of previous transplantation, glomerulonephritis, systemic lupus erythematosus, and vasculitis.
Introduction

Continuous ambulatory peritoneal dialysis (CAPD) is a safe, relatively inexpensive, and effective alternative
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to haemodialysis in the treatment of end-stage renal failure. Infectious peritonitis is the major complication limiting the usefulness of this therapy. Improvements in equipment and technique, especially the introduction of the Y set/disconnect systems, have led to a marked reduction in the incidence of CAPD peritonitis from over two episodes/patient year in 1979 to less than one episode/patient year in 1989 [1] . Recently, however, a plateau appears to have been reached, with an incidence of 0.5-1.0 episodes of peritonitis/patient year becoming usual in many centres [2] . In those episodes of peritonitis where an organism is identified, approximately 30-50% of cases are attributable to coagulasenegative staphylococci, 25% to Gram-negative bacilli, 10-25% to S. aureus, 10% to other Gram-positive cocci, and 5% to fungal or other unusual organisms [3] . Immunosuppression has been suggested as an important predisposing factor for fungal [4] or unusual [5] organisms. However, the precise role of immunosuppression as a predisposing factor for CAPD peritonitis, as well as the outcome of such episodes, remains uncertain. We therefore investigated the incidence, spectrum of infectious organisms, and outcome of CAPD peritonitis in immunosuppressed (IS) and nonimmunosuppressed (NIS) patients.
Methods
The case records were reviewed of all patients who underwent CAPD at Guy's Hospital during the calendar year 1993. For each patient, the following information was collected: age, sex, race, cause of renal failure, length of time on CAPD, and months on CAPD during 1993. Details related to episodes of peritonitis included the organism responsible, requirement for CAPD catheter removal, number of days as an inpatient, number of days off" CAPD, and outcome. CAPD peritonitis was diagnosed if two out of three of the following criteria were met: (1) signs and/or symptoms of peritonitis; (2) cloudy dialysate fluid; (3) > 100 leukocytes/ millilitre dialysate + the presence of micro-organisms in the dialysate fluid. Episodes of peritonitis were identified from the case notes and cross referenced with laboratory and nursing staff records. Exit site infections were not recorded.
Patients were assigned to the IS group if they were receiving immunosuppressive therapy, had received such therapy in the 12 months immediately prior to the study period, or if they had active disease that was likely to predispose to infection (HIV infection, bone-marrow suppression, or primary blood dyscrasia). Details of immunosuppression examined included the drugs used, indications for therapy, and the presence or absence of diabetes.
Statistical analyses of time-dependent variables were performed using the Mann-Whitney U test, while comparisons between groups were performed using yj with two degrees of freedom or ANOVA. Significance was taken as P<0.05.
Results
One hundred and eighty-seven patients received CAPD during all or part of the calendar year 1993, and sufficient data was obtained for analysis in 185. Thirtynine patients were assigned to the IS group and 146 to the NIS. All 39 patients in the IS group were currently receiving imrnunosuppressive therapy (n = 28) or had received immunosuppressive therapy in the recent past (n = ll). The indications for immunosuppressive therapy were: failed renal transplant (24), vasculitis (6), systemic lupus erythematosus (SLE) (4), treatment of myelodysplastic disorder (3), sarcoidosis (1) , and cardiac transplantation (1). The immunosuppressive agents used included prednisolone alone in six patients, prednisolone and azathioprine (7), prednisolone and cyclosporin (2), prednisolone with azathioprine and cyclosporin (14) , prednisolone and cyclophosphamide (7), and cyclophosphamide followed by azathioprine and prednisolone (3) . Fourteen patients received intravenous pulses of methylprednisolone (usually 3 g over 3 days), and eight received either monoclonal (0KT3) or polyclonal (antithymocyte or antilymphocyte) antibody therapy in addition to their baseline oral therapy.
Demographic data for the two groups is shown in Table 1 . IS patients were younger, as might be expected given the higher incidence of failed transplantation in this age group. The groups did not differ significantly in sex ratio, racial background, or duration of CAPD. The duration of renal replacement therapy was shorter in the IS patients. This is partly explained by an analysis of underlying renal disease (Table 2) , which shows an increased incidence of SLE, glomerulonephritis, and vasculitis in the IS group, all of which were commoner in younger patients who had spent less time on renal replacement therapy. In contrast, patients with diabetes and hypertension were older and less likely to have received immunosuppression, the latter due to underlying pathology, and also to selection bias against renal transplantation in patients with intercurrent medical problems.
One hundred and eighty-five patients received CAPD for 1632 months in the calendar year 1993 (mean 8.8 months/patient). There were 168 episodes of CAPD peritonitis, representing a rate of 0.8 episodes/patientyear. IS patients had significantly more episodes of peritonitis than the NIS group: 69 in 39 patients vs 99 in 146 (1.8 vs 0.68 episodes/patient-year; P<0.001, Mann-Whitney). Peritonitis rates within the IS group were increased irrespective of whether immunosuppression was ongoing, or had ceased within the previous 12 months (1.6 and 1.7 episodes peritonitis/patient year respectively). The spectrum of organisms causing peritonitis was similar in the IS and NIS groups (Table 3) . However, there were trends towards an increased incidence of S. aureus(\9 vs 10%) and fungal peritonitis (6 of 9 episodes) in the IS group; and towards an increased incidence of peritonitis due to Gram-negative rods (18 vs 12%) in the NIS group. All six episodes of fungal peritonitis in the IS group occurred following recent multiple episodes of treated bacterial peritonitis; while, in the NIS group, two of three occurred in diabetic patients, and the other followed multiple episodes of treated bacterial peritonitis. Diabetes did not predispose to CAPD peritonitis (22 episodes peritonitis in 27 diabetic vs 146 in 158 non-diabetic patients; / ) = NS, Mann-Whitney). There was only one death directly attributable to infection, occurring in a patient with vasculitis who had received heavy immunosuppression and who developed fungal peritonitis, followed by fungal empyema and septicaemia. ). There was a trend for an increased incidence of peritonitis in patients with vasculitis, although differences between groups were not statistically significant (Table 5 ). In contrast, vasculitis was significantly associated with fungal peritonitis (P<0.05, x 2 ), possibly reflecting an increased immunosuppressive burden in this group.
Analysis of peritonitis rates in relation to the severity of immunosuppression showed a trend for the incidence of peritonitis to parallel the aggressiveness of immunosuppression, particularly with cyclophosphamide and antilymphocyte antibody therapy (Table 6) . Although formal analysis of peritonitis rates for each immunosuppressive agent showed no statistically significant differences, either alone or in combination, the small numbers in each group mean that real differences may not have been detected. Notably, five of the six immunosuppressed patients with fungal peritonitis had received a combination of cyclophosphamide and methylprednisolone, whilst the sixth received prednisolone alone; none had received antilymphocyte antibody therapy.
Discussion
It is widely accepted that patients with renal failure have an increased risk of infection, in part due to defects of both cellular and humoral immunity [6] . Factors specific to CAPD, such as the production of extracellular slime, may further predispose to catheterrelated peritonitis, which remains the major complication limiting the usefulness and longevity of this mode of therapy [3, [7] [8] [9] . Given this background, we hypothesized that immunosuppression might be an additional risk factor for CAPD peritonitis, exacerbating patients' pre-existing susceptibility to infection. Our results show that patients treated with immunosuppressive agents, or who have recently received such treatment, are two to three times more likely to suffer CAPD peritonitis than those not receiving immunosuppression. These results are consistent with previous reports of an increased incidence of fungal peritonitis in patients with human immunodeficiency virus, and also an increased incidence of unusual organisms in immunosuppressed patients, both of which are associated with poor technique and patient survival [4, 5, [10] [11] [12] . The results thus have implications for the optimal route of dialysis for such patients, and for the management of suspected or established infection.
The overall spectrum and distribution of organisms causing peritonitis was not significantly different between the two groups. However, three trends require further consideration. First, there was an increase in S. aureus peritonitis in the IS group, with a concomitant decrease in peritonitis due to coagulase-negative staphylococci. Since S. aureus peritonitis is more severe than that due to coagulase-negative staphylococci [13] , this may in part explain the difference in morbidity between the two groups. We cannot comment on the nasal carriage of S. aureus in our patients, as this was not systematically documented over this period. Second, there was a strong trend towards increased fungal infection in the IS group, which had six of the nine episodes of fungal peritonitis, as well as the only infection-related death. This association might have resulted from a direct effect of the immunosuppressive agent on host defences, or from an increased incidence of bacterial peritonitis, when intraperitoneal antibiotic therapy might have predisposed to fungal overgrowth and peritonitis [4] . Third, the trend towards an increased incidence of Gram-negative sepsis in the NIS group may have reflected the increased mean age of this group, with an increased incidence of colonic diverticulosis [3] .
Peritonitis is a major source of morbidity and technique failure in CAPD. Patients who had received immunosuppression had more severe episodes of peritonitis, as evidenced by the increased proportion requiring hospital admission for treatment of their peritonitis. They also spent more days in hospital during each admission and were more likely to require laparotomy for removal of a dialysis catheter to treat their peritonitis. These important differences in morbidity may be a direct consequence of the different incidence of episodes of peritonitis due to S. aureus and fungi in the two groups, although intercurrent medical problems may also have contributed.
There was no statistically significant correlation between the incidence of peritonitis and the indication for immunosuppression. Although fungal peritonitis was commoner in patients with vasculitis, numbers were small and this finding will require confirmation. There was, however, a trend towards an increase in peritonitis, especially fungal peritonitis, with increased immunosuppressive load. Despite this trend, however, none of the individual immunosuppressive agents were significantly associated with peritonitis, either alone or in combination. Thus, it appears to be the combination of immunosuppressive agents and underlying pathology that is important in the increased susceptibility to infection. Although we did not directly assess this issue, the timing of immunosuppression is also likely to be important. In this context, it is noteworthy that the increased incidence of infection in the IS group occurred irrespective of whether IS was ongoing, or had occurred within the previous 12 months. This is consistent with emerging evidence that deficits of cellular immunity may persist for many years after immunosuppression, particularly in patients treated with antilymphocyte therapy [14, 15] .
In summary, immunosuppression appears to be associated with an increased incidence of CAPD peritonitis, and in turn with increased morbidity, hospital admission, catheter loss, and technique failure. A number of important conclusions follow. We suggest that CAPD should be deferred in patients who have recently received immunosuppression, unless permanent vascular access is not available, when the extra risks associated with temporary access may exceed those of CAPD. Our own practice is now to recommend haemodialysis for patients in receipt of methylprednisolone, cyclophosphamide, or antilymphocyte therapy within the 6 months prior to dialysis, and also to ensure the provision of adequate vascular access. If CAPD is used in immunosuppressed patients, we recommend that disconnect systems should be employed, since the extra expense is offset by significant reduction in peritonitis rates [1] . A high index of suspicion for infection should be maintained, particularly for fungi. Lastly, although not directly assessed by this study, the increased incidence of S. aureus peritonitis in the IS group suggests that nasal carriage of S. aureus and exit-site infections should be treated aggressively [16] , and with a low threshold for catheter removal.
